MedTrace Logo

Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01079897 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2011-10-18

No results posted yet for this study

Summary

This study evaluates the efficacy of the topical used ectoine-formulation EHK02-01 compared to Atopiclair. Patients are examined at visit 2 (baseline visit). The patient topically applies EHK02-01 or Zarzenda® twice daily on two symmetric lesional areas over 28 days. Response to therapy is recorded at each visit.

Conditions

  • Mild to Moderate Atopic Dermatitis

Interventions

DEVICE

Atopiclair

topical applied cream, twice daily

DEVICE

EHK02-01

topical applied cream containing 7% ectoine

Sponsors & Collaborators

  • Bitop AG

    lead INDUSTRY

Principal Investigators

  • Wolfgang Vanscheidt, Professor · Professor Dr. med Wolfgang Vanscheid (Hautarzt, Allergologie, Phlebologie)

  • Tanja Fischer, Dr. · Haut- und Lasercentrum Potsdam

  • Martin Miehe, Dr. · Hautarztzentrum Tegel

  • Michael Sebastian, Dr. · Facharzt für Dermatologie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079897 on ClinicalTrials.gov